Esperion(ESPR) - 2025 Q2 - Quarterly Results

Financial Performance - Q2 2025 total revenue increased by 12% year-over-year to $82.4 million, with U.S. net product revenue growing by 42% year-over-year to $40.3 million[1][9] - Total revenues for the three months ended June 30, 2025, increased to $82,385,000, a 11% rise from $73,834,000 in the same period of 2024[32] - Product sales, net for the six months ended June 30, 2025, reached $75,187,000, up 42% from $53,058,000 in 2024[32] - Collaboration revenue for Q2 2025 was $42.1 million, a decrease of approximately 7% year-over-year, but excluding one-time milestones, it grew by approximately 105%[1][9] - Collaboration revenue for the three months ended June 30, 2025, was $42,111,000, a decrease of 8% compared to $45,532,000 in 2024[32] - The company reported an income from operations of $15,029,000 for the three months ended June 30, 2025, compared to $2,579,000 in 2024[32] - The net loss for the three months ended June 30, 2025, was $4,791,000, significantly improved from a net loss of $61,925,000 in the same period of 2024[32] Operating Expenses - The company anticipates full-year 2025 operating expenses to be in the range of $215 million to $235 million, including approximately $15 million in non-cash stock compensation expenses[1][12] - Total operating expenses for the three months ended June 30, 2025, were $67,356,000, a decrease of 5% from $71,255,000 in 2024[32] - Research and development expenses decreased by 37% year-over-year to $7.2 million for Q2 2025, primarily due to reduced costs for ongoing clinical studies[1][9] - Research and development expenses decreased to $7,238,000 for the three months ended June 30, 2025, from $11,461,000 in 2024, reflecting a 37% reduction[32] Cash Position - Cash and cash equivalents as of June 30, 2025, totaled $86.1 million, down from $144.8 million as of December 31, 2024[1][10] - Cash and cash equivalents as of June 30, 2025, were $86,061,000, compared to $144,761,000 as of December 31, 2024[30] Strategic Initiatives - Esperion expects to achieve sustainable profitability starting in Q1 2026, supported by strong revenue growth and strategic initiatives[1][12] - The company reached settlement agreements with three ANDA filers to prevent the marketing of generic versions of NEXLETOL until 2040, reinforcing its intellectual property protection[1][4] Market Performance - Total retail prescription equivalents rose by approximately 10% from the first quarter of 2025, with over 28,000 healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET[1][6] - Esperion's European partner, Daiichi Sankyo Europe, reported strong revenue growth, surpassing 500,000 patients for NILEMDO and NUSTENDI, with royalty revenue increasing by 30% sequentially to $13.6 million[1][6] Accumulated Deficit - The accumulated deficit increased to $(1,646,275,000) as of June 30, 2025, from $(1,601,029,000) as of December 31, 2024[30]